Prevention Of Primary Graft Dysfunction (“PGD”) In Lung Transplant Recipients
Utilizing the same single gas-device-software-dosing combination product as for DGF, we are planning an IND filing in 2025 and clinical trials treating lung transplant recipients inhaled CO in order to reduce primary graft dysfunction (“PGD”) post-operatively. PGD occurs with higher frequency (i.e., upwards of 50%) and with even more dire outcome consequences (especially mortality) than DGF in kidney transplant.
